BPD treatments: The never-ending smorgasbord

Area of Science:

• Neonatal Medicine
• Pediatric Pulmonology
• Respiratory Physiology

Background:

• Bronchopulmonary dysplasia (BPD) continues to affect a significant number of neonates despite advances in care.
• Current therapeutic strategies for BPD exhibit variable efficacy and safety profiles.
• There is a critical need to evaluate existing and emerging treatments for BPD.

Purpose of the Study:

• To review and classify current therapies for bronchopulmonary dysplasia (BPD) based on evidence of effectiveness.
• To critically assess treatments with limited or conflicting evidence for BPD.
• To explore novel approaches for preventing or mitigating BPD and associated long-term respiratory issues.

Main Methods:

• Systematic review and evidence-based classification of BPD therapies.
• Analysis of clinical trial data and meta-analyses for efficacy and safety.
• Exploration of emerging research and therapeutic targets for BPD.

Main Results:

• Exogenous surfactant, volume-targeted ventilation, caffeine, and non-invasive support demonstrate efficacy in reducing BPD rates.
• Corticosteroids, diuretics, nitric oxide, bronchodilators, and anti-reflux medications have limited or conflicting evidence of benefit.
• Emerging therapies show promise for improved BPD outcomes.

Conclusions:

• Evidence-based therapies offer modest but significant reductions in BPD and respiratory morbidity.
• Many widely used BPD treatments lack robust evidence, highlighting a need for cautious application.
• Further research into novel therapeutic strategies is essential for improving neonatal respiratory health and reducing long-term sequelae.